Results 131 to 140 of about 52,189 (266)

A versatile and GMP-compliant bead-based IFN-γ potency assay for standardized quality control and release testing of CAR-T cell drug products. [PDF]

Int J Pharm X
Dennebos R, González-Corrales M, Lysandrou M, Smit NAM, Qi Y, van Meerten T, Kosterink JGW, Huls G, Lourens HJ, Gareb B, Bremer E.   +10 more
europepmc   +1 more source

Clinical predictors of response to methotrexate in patients with rheumatoid arthritis: A systematic review

Rheumatology &Autoimmunity, EarlyView.
This review integrates clinical, immunological, genetic, and multi‐omic evidence, highlighting dynamic inflammatory and adenosine‐pathway biomarkers and reinforcing treat‐to‐target principles as the most actionable framework for personalized methotrexate therapy.
Joana Ramos Rodrigues, Helena Margarida de Miranda Lemos Romão Donato, Soraia Raquel Loureiro Azevedo, Luís Miguel da Silva Pires, Luís Pedro Bolotinha de Sousa Inês, Manuel Augusto Nunes Vicente Passos Morgado, Ana Filipa de Sousa Pestana Mourão   +6 more
wiley   +1 more source

Challenges and opportunities: CAR-T cell therapy in autoimmune diseases. [PDF]

Cell Insight
Yan R, Ye S, Xu H.
europepmc   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

Engineering programmable CAR and antigen pairing via drug-gated light activation. [PDF]

Nat Commun
Huang Z, Limsakul P, Wu Y, Guo T, Wang Y, Wu Z, Zhu L, Allen ME, Liu L, Wang Y.   +9 more
europepmc   +1 more source

Peptide‐directed nanovehicles enabling tumor‐selective ROS amplification and antitumor immunity

VIEW, EarlyView.
Cancer cells are vulnerable to oxidative stress, yet exploit immune tolerance to escape destruction. In contrast, their metabolic profile is markedly altered to support rapid proliferation, accompanied by elevated production of reactive oxygen species (ROS).
Manuela Calin, Galyna Bila, Ileana Manduteanu, Rostyslav Bilyy   +3 more
wiley   +1 more source

Dual-target CAR-T cell therapy: latest updates from the 2025 ASH annual meeting. [PDF]

Exp Hematol Oncol
Feng S, Kong R, Xiao L, Zhou X.
europepmc   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source

Chimeric Antigen Receptor T-Cell Revolution Remodeling Immunity to Conquer Autoimmune Disease. [PDF]

Research (Wash D C)
Shao W, Liu J, Sun M, Yu D.
europepmc   +1 more source

Nanomedicine applications in lymphoma: Advancing precision diagnostics, targeted therapeutics, and prospective developments

VIEW, EarlyView.
Lymphoma is a group of blood cancers that can appear in lymph nodes, blood, bone marrow, spleen, liver, or the central nervous system, which makes drug delivery and disease monitoring difficult. This review summarizes how nanomedicine technologies may improve targeted treatment and imaging, while carefully separating approved or guideline‐supported ...
Mohd Ahmar Rauf, Yara Mashal, Afeefa Rao, Nasar Ata, Arun K. Iyer, Farhan Shah   +5 more
wiley   +1 more source